Keywords: تمسیرولیموس; mTOR inhibitor; Temsirolimus; Interstitial lung disease; Drug-induced pneumonia; Acute exacerbation; AaDO2; alveolar-arterial oxygen gradient; CMV; cytomegalovirus; CRP; C-reactive protein; DAD; diffuse alveolar damage; DILD; Drug-induced interstitial lun
مقالات ISI تمسیرولیموس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: تمسیرولیموس; Everolimus; mTOR inhibitor; Targeted therapy; Temsirolimus; Treatment-naive
Keywords: تمسیرولیموس; Renal cell carcinoma; Non-clear cell; Metastatic; Papillary; Chromophobe; Systemic therapy; Targeted therapy; Temsirolimus; Sunitinib; Sorafenib
Keywords: تمسیرولیموس; Renal cell carcinoma; Sequential therapy; Survival; Sunitinib; Sorafenib; Everolimus; Bevacizumab; Axitinib; Temsirolimus; Third-line;
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
Keywords: تمسیرولیموس; Metastasis; MiT family translocation tumor; Papillary renal cell carcinoma; Temsirolimus; VEGFR TKI;
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
Keywords: تمسیرولیموس; Endometrial cancer; Paclitaxel; Carboplatin; Bevacizumab; Temsirolimus; Ixabepilone;
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
Keywords: تمسیرولیموس; Sorafenib; Advanced osteosarcoma; Denosumab; Everolimus; Novel therapy; Second line; RANKL; Tyrosine kinase; Nexavar; MTORC; Italian Sarcoma Group; Primary bone cancer; MAPK; ERK; Temsirolimus; Bevacizumab;
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
Keywords: تمسیرولیموس; Ovarian cancer; Endometrial cancer; Temsirolimus; mTOR inhibitor; Rapalog
Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data
Keywords: تمسیرولیموس; Ovarian cancer; Endometrial cancer; Cervical cancer; Everolimus; Temsirolimus;
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Keywords: تمسیرولیموس; Bevacizumab; Renal cell carcinoma; Temsirolimus; TKI-refractory disease;
Temsirolimus therapy and small bowel perforation in a pediatric patient with Clostridium septicum bacteremia
Keywords: تمسیرولیموس; Rhabdomyosarcoma; Temsirolimus; Clostridium septicum; Gastrointestinal perforationCT, computed Tomography; FDA, United States Food and Drug Administration; HIF-1α, hypoxia-inducible factor alpha-1; IFN-α, interferon-alpha; mTOR, mammalian target of rapamy
mTOR inhibitors and diabetes
Keywords: تمسیرولیموس; mTOR inhibitors; Diabetes; Hyperglycemia; Cancer; Everolimus; Temsirolimus
Cáncer de mama con receptores hormonales positivos: tratamiento adyuvante, primera línea en cáncer metastásico y nuevas estrategias (inhibición de mTOR)
Keywords: تمسیرولیموس; Cáncer de mama; Resistencia endocrina; Everolimus; Inhibidores de mTOR; TemsirolimusBreast cancer; Endocrine resistance; Everolimus; mTOR inhibitors; Temsirolimus
A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer
Keywords: تمسیرولیموس; Non–small-cell lung cancer; Radiation; Temsirolimus
Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: In vitro and in vivo
Keywords: تمسیرولیموس; Autophagy; mTOR; Adenoid cystic carcinoma; Temsirolimus
Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer
Keywords: تمسیرولیموس; Renal cell carcinoma; Temsirolimus; TEMSR; mTOR inhibitor; Prospective clinical trial; Study; Prognosis; Toxicity
Metabolic complications with the use of mTOR inhibitors for cancer therapy
Keywords: تمسیرولیموس; Cancer; mTOR inhibitor; Metabolic; Temsirolimus; Everolimus; Ridaforolimus; Adverse events;
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
Keywords: تمسیرولیموس; Temsirolimus; Hormonal therapy; Megestrol acetate; Tamoxifen; Endometrial cancer;
Treatment of muscle invasive urinary bladders tumors: A potential role of the mTOR inhibitors
Keywords: تمسیرولیموس; Gemcitabine; Cisplatin; Temsirolimus; Everolimus; Combined antineoplastic chemotherapy; Cancer cell lines
Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease
Keywords: تمسیرولیموس; Temsirolimus (PubChem CID: 6918289); 3-Methyladenine (PubChem CID: 1673); Alzheimer's disease; Temsirolimus; Autophagy; Amyloid-β; Spatial cognitive deficits;
Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance
Keywords: تمسیرولیموس; Temsirolimus; Tauopathy; Autophagy; GSK-3β; Spatial cognitive deficits;
Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines
Keywords: تمسیرولیموس; Bladder cancer cell lines; Temsirolimus; Cisplatin; Gemcitabine; Combination chemotherapy;
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer
Keywords: تمسیرولیموس; Temsirolimus; mTOR inhibitors; Endometrial cancer; Predictors of response;
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
Keywords: تمسیرولیموس; Temsirolimus; Bevacizumab; Recurrent endometrial cancer; Phase II; GOG;
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
Keywords: تمسیرولیموس; Cervical cancer systemic therapy; Temsirolimus; Phase II trial; mTOR pathway;
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
Keywords: تمسیرولیموس; Temsirolimus; Erlotinib; Platinum-refractory; Head and neck squamous cell carcinoma; mTOR; EGFR; PIK3CA
Evidence and experience for the management of metastatic renal cell carcinoma
Keywords: تمسیرولیموس; Metastatic renal cell carcinoma; mRCC; Sunitinib; Axitinib; Temsirolimus; Guidelines; Sequencing
Hepatic arterial infusion of temsirolimus inhibits tumor growth of colorectal rat liver metastases even after a growth stimulating procedure like liver resection
Keywords: تمسیرولیموس; Hepatic arterial infusion; Temsirolimus; Colorectal liver metastases; Proliferation; Apoptosis; Vascularization
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
Keywords: تمسیرولیموس; Dose escalation; Maximum tolerated dose; Pharmacokinetics; Renal cell carcinoma; Tivozanib; Temsirolimus
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Keywords: تمسیرولیموس; Castration-resistant; Circulating tumor cells; Epithelial-mesenchymal transition; Metastatic prostate cancer; mTOR; N-cadherin; Prostate-specific antigen; Temsirolimus
Differentiating mTOR inhibitors in renal cell carcinoma
Keywords: تمسیرولیموس; mTOR inhibitors; Renal cell carcinoma; Temsirolimus; Everolimus; Treatment; PI3K/Akt/mTOR pathway
Gene expression changes associated with erlotinib response in glioma cell lines
Keywords: تمسیرولیموس; Gliomas; Glioblastoma multiforme; Glioma cell lines; Microarray expression assays; Epidermal growth factor receptor; Erlotinib; Temsirolimus; PTEN; PI3K/Akt pathway; MAPK/Erk pathway
mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice
Keywords: تمسیرولیموس; Temsirolimus; Everolimus; Kidney cancer; mTOR inhibitors
Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
Keywords: تمسیرولیموس; mTOR inhibitors; Advanced non–small-cell lung carcinoma; Temsirolimus; Window of opportunity
mTOR pathway inhibition in renal cell carcinoma
Keywords: تمسیرولیموس; mTOR; Renal cell carcinoma; Temsirolimus; Everolimus
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
Keywords: تمسیرولیموس; Renal cell carcinoma; Temsirolimus; Everolimus; Mammalian target of rapamycin (mTOR) inhibitors; Lung toxicity;
Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
Keywords: تمسیرولیموس; Everolimus; Metastatic renal cell carcinoma; Sorafenib; Temsirolimus; Tyrosine kinase inhibitor
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
Keywords: تمسیرولیموس; Cancer; mTOR inhibitor; Renal cell carcinoma; Skin rash; Stomatitis; Temsirolimus
Stability of ready-to-use temsirolimus infusion solution (100Â mg/L) in polypropylene containers under different storage conditions
Keywords: تمسیرولیموس; Temsirolimus; Infusion solutions; 100 mg/L; Polypropylene bags; Stability; Different storage conditions; Temsirolimus; Solutions reconstituées; 100 mg/L; Poches en polypropylène; Stabilité; Différentes conditions de stockage;
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
Keywords: تمسیرولیموس; mTOR; Endometrial cancer; Ovarian cancer; Cervical cancer; Temsirolimus; Everolimus; Ridaforolimus
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Keywords: تمسیرولیموس; Temsirolimus; mTOR; Child; Adolescent; Glioma; Neuroblastoma; Rhabdomyosarcoma; Clinical trial; Phase II;
mTOR inhibitors in breast cancer: A systematic review
Keywords: تمسیرولیموس; Breast cancer; mTOR inhibitor; Everolimus; Temsirolimus; Systematic review;
Hydrogel containing l-valine residues as a platform for cisplatin chemotherapy
Keywords: تمسیرولیموس; Stimuli-responsive hydrogels; Cisplatin chemotherapy; Zero-order release; Temsirolimus; Melanoma cells
Inhibiteurs de mTOR : de l'explication biologique à l'application thérapeutique en hématologie
Keywords: تمسیرولیموس; inhibiteurs mTOR; hémopathie; biologie; évérolimus; temsirolimus; mTOR inhibitors; haematology diseases; biology; everolimus; temsirolimus;
Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy
Keywords: تمسیرولیموس; Mesothelioma; mTOR; Temsirolimus; Chemotherapy; Cisplatin resistance
Mantle cell lymphoma: The promise of new treatment options
Keywords: تمسیرولیموس; Mantle cell lymphoma; Non-Hodgkin's lymphoma; Rituximab; Bortezomib; Flavopiridol; Bendamustine; Temsirolimus; Lenalidomide
Neoadjuvant Temsirolimus Effectiveness in Downstaging Advanced Non–Clear Cell Renal Cell Carcinoma
Keywords: تمسیرولیموس; Temsirolimus; Non–clear cell renal cell carcinoma; Neoadjuvant
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
Keywords: تمسیرولیموس; Phase I; Temsirolimus
Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
Keywords: تمسیرولیموس; Renal cell carcinoma; Patient-focused; Treatment approach; Targeted agent; Sorafenib; Sunitinib; Bevacizumab; Temsirolimus; Everolimus
The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice
Keywords: تمسیرولیموس; IL-2; Delayed-type hypersensitivity; Cyclosporine A; Cell signaling; Costimulation; T cells; Cytokines; mTOR; Temsirolimus; CTLA-4